Epertinib
| CAS No. | 908305-13-5 | Cat. No. | BCP29362 |
| Name | Epertinib | ||
| Synonyms | S-222611; S222611; S 222611; | ||
| Formula | C30H27ClFN5O3 | M. Wt | 560.02 |
| Description | Epertinib, also known as S-222611, is an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, currently under trials in patients with solid tumours. S-222611 selectively inhibited kinases with IC50 s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | EGFR HER2 | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.